EVGN Stock — Evogene

Evogene (EVGN)

Updated October 16, 2026.

EVGN is a Stock. Its deepest 1-year drawdown was 71.0%.

Evogene Ltd. is a computational biology company based in Israel that develops agricultural seeds and traits, novel drug compounds using artificial intelligence, industrial castor bean seeds, and medical cannabis products. The company does not currently have an established distribution schedule. Evogene appeals to investors seeking exposure to biotechnology and agricultural innovation, though it is an early-stage development company without predictable income generation.

EVGN performance

Returns are updating. EVGN's total return appears here after the next nightly update.

Its deepest 1-year drawdown was 71.0%.

EVGN key facts

Asset type

Stock

Asset class

Equity

Inception date

03/05/2008

Distribution frequency

None

Last close

$0.39 (as of 2026-10-16)

Market cap

$6,102,503

Average volume

37674.0

Beta

0.716

Payout ratio

0.0%

EPS

$-1.55

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

EVGN risks and drawbacks

The deepest 1-year drawdown on record here is 71.0%.

Who may consider EVGN — and who may not

It is a weaker fit for investors who need monthly cash flow (EVGN does not currently distribute). This is educational context, not a recommendation to buy or sell.

More on EVGN

• All tickers starting with E

Tagged: Healthcare.

Frequently asked questions